UbiVac CEO Bernard A. Fox to Head Discussion on Immunotherapy and Translational Oncology at Providence Cancer Center
October 15, 2015
Portland, Ore.—Internationally known immuno-oncologist Bernard A. Fox, PhD, chief executive officer of UbiVac, www.ubivac.com , will be heading a panel of specialists speaking on October 20, 6:00 to 8:00 pm, at the Earle A. Chiles Research Institute (EACRI) at the Providence Cancer Center. Dr. Fox also is the Harder Family Chair for Cancer Research, member and chief, Laboratory of Molecular and Tumor Immunology at EACRI.
The presentation is sponsored by the Oregon Bioscience Association.
The panel will highlight advances in immuno-oncology therapy, one of the most promising areas making significant strides in cancer treatment today.
Panelists and colleagues joining Dr. Fox are:
Brendan Curti, M.D., director, genitourinary oncology research and biotherapy clinical program, EACRI;
Hong-Ming, PhD, chief, Laboratory of Cancer Immunology, EACRI, and chief scientific officer at UbiVac;
William Redmond, PhD, assistant member, Laboratory of Cancer Immunology, EACRI;
Andrew Weinberg, PhD, chief, Laboratory of Basic Immunology, EACRI and president and chief scientific officer, AgonOx;
Emmanuel Akporiaye, PhD, division chief of experimental biology, Sidra Medical and Research Center, Doha, Qatar, adjunct member, EACRI and chief executive officer, Veana Therapeutics.
The Earle A. Chiles Research Institute, Providence Cancer Center, is located at 819 NE 47th Avenue, Portland. Please make reservations via the Oregon Bioscience Association www.oregonbio.org.
UbiVac is a clinical stage, Immuno-Oncology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 is currently in a phase II randomized multicenter adjuvant study for non-small cell lung cancer. UbiVac has ongoing preclinical and discovery programs using DRibble, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005 by Drs. Bernard A Fox and Hong-Ming Hu, UviVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health and Science University, created UbiVac CMV to license sdCMV.